Ciclopirox
Loprox (ciclopirox) is a small molecule pharmaceutical. Ciclopirox was first approved as Loprox on 1982-12-30. It is used to treat cutaneous candidiasis, onychomycosis, tinea pedis, and tinea versicolor in the USA. It is known to target poly [ADP-ribose] polymerase 1.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Loprox (generic drugs available since 2004-08-06, discontinued: Penlac)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ciclopirox | ANDA | 2023-06-15 |
| loprox | New Drug Application | 2019-05-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| cutaneous candidiasis | — | D002179 | — |
| onychomycosis | — | D014009 | B35.1 |
| tinea pedis | EFO_0007512 | D014008 | B35.3 |
| tinea versicolor | EFO_0007439 | D014010 | B36.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D01: Antifungals for dermatological use
— D01A: Antifungals for topical use
— D01AE: Other antifungals for topical use in atc
— D01AE14: Ciclopirox
G: Genito urinary system and sex hormones
— G01: Gynecological antiinfectives and antiseptics
— G01A: Antiinfectives and antiseptics, excl. combinations with corticosteroids
— G01AX: Other gynecological antiinfectives and antiseptics in atc
— G01AX12: Ciclopirox
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CICLOPIROX |
| INN | ciclopirox |
| Description | Ciclopirox is a cyclic hydroxamic acid that is 1-hydroxypyridin-2(1H)-one in which the hydrogens at positions 4 and 6 are substituted by methyl and cyclohexyl groups, respectively. A broad spectrum antigfungal agent, it also exhibits antibacterial activity against many Gram-positive and Gram-negative bacteria, and has anti-inflammatory properties. It is used a a topical treatment of fungal skin and nail infections. It has a role as an antibacterial agent and an antiseborrheic. It is a pyridone, a cyclic hydroxamic acid and a hydroxypyridone antifungal drug. |
| Classification | Small molecule |
| Drug class | antimycotics (pyridone derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Cc1cc(C2CCCCC2)n(O)c(=O)c1 |
Identifiers
| PDB | — |
| CAS-ID | 29342-05-0 |
| RxCUI | 21090 |
| ChEMBL ID | CHEMBL1413 |
| ChEBI ID | 453011 |
| PubChem CID | 2749 |
| DrugBank | DB01188 |
| UNII ID | 19W019ZDRJ (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
PARP1
PARP1
Organism
Homo sapiens
Gene name
PARP1
Gene synonyms
ADPRT, PPOL
NCBI Gene ID
Protein name
poly [ADP-ribose] polymerase 1
Protein synonyms
ADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase), ADP-ribosyltransferase diphtheria toxin-like 1, ADP-ribosyltransferase NAD(+), ADPRT 1, ARTD1, DNA ADP-ribosyltransferase PARP1, NAD(+) ADP-ribosyltransferase 1, poly (ADP-ribose) polymerase family, member 1, poly(ADP-ribose) synthetase, poly(ADP-ribosyl)transferase, Poly[ADP-ribose] synthase 1, Protein poly-ADP-ribosyltransferase PARP1
Uniprot ID
Mouse ortholog
Parp1 (11545)
poly [ADP-ribose] polymerase 1 (P11103)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,578 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more